Abstract
Nicotinic acetylcholine receptors (nAChR) have been strongly implicated as therapeutic targets for treating cognitive deficits in disorders such as schizophrenia and Alzheimers disease (AD). In particular α7 and α4β2 subtypeselective nAChR agonists and partial agonists have been developed as potential candidates for the treatment of schizophrenia, cognitive disorders (including Alzheimers disease), and inflammation. Further development of positive allosteric modulators were also recently reported in the literature. In this review we will cover recent developments focused on the above mentioned nAChR subtypes, starting from the most advanced clinical candidate followed by an overview of literature compounds where potency, selectivity, central nervous system access, pharmacological activity and pharmacokinetic properties are disclosed.
Current Topics in Medicinal Chemistry
Title: Neuronal Nicotinic Acetylcholine Receptors - Targets for the Development of Drugs to Treat Cognitive Impairment Associated with Schizophrenia and Alzheimers Disease
Volume: 10 Issue: 2
Author(s): Simon N. Haydar and John Dunlop
Affiliation:
Abstract: Nicotinic acetylcholine receptors (nAChR) have been strongly implicated as therapeutic targets for treating cognitive deficits in disorders such as schizophrenia and Alzheimers disease (AD). In particular α7 and α4β2 subtypeselective nAChR agonists and partial agonists have been developed as potential candidates for the treatment of schizophrenia, cognitive disorders (including Alzheimers disease), and inflammation. Further development of positive allosteric modulators were also recently reported in the literature. In this review we will cover recent developments focused on the above mentioned nAChR subtypes, starting from the most advanced clinical candidate followed by an overview of literature compounds where potency, selectivity, central nervous system access, pharmacological activity and pharmacokinetic properties are disclosed.
Export Options
About this article
Cite this article as:
Haydar N. Simon and Dunlop John, Neuronal Nicotinic Acetylcholine Receptors - Targets for the Development of Drugs to Treat Cognitive Impairment Associated with Schizophrenia and Alzheimers Disease, Current Topics in Medicinal Chemistry 2010; 10 (2) . https://dx.doi.org/10.2174/156802610790410983
DOI https://dx.doi.org/10.2174/156802610790410983 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Allele Frequency Distributions of the Drug Metabolizer Genes <i>CYP2C9*2</i>, <i>CYP2C9*3</i>, and <i>CYP2C19*17</i> in the Buginese Population of Indonesia
Current Pharmacogenomics and Personalized Medicine Critical Review on the Chemical Aspects of Cannabidiol (CBD) and Harmonization of Computational Bioactivity Data
Current Medicinal Chemistry Commentary: Recalling Memory by Brain Stimulation
CNS & Neurological Disorders - Drug Targets Synthesis and Anticonvulsant Activity of Some Novel 2-Methyl Imidazole Derivatives
Letters in Drug Design & Discovery Na+ Channel Pharmacology and Molecular Mechanisms of Gating
Current Pharmaceutical Design Neuroprotective Effects of Drug-Induced Therapeutic Hypothermia in Central Nervous System Diseases
Current Drug Targets Pharmacological Intervention at Ionotropic Glutamate Receptor Complexes
Current Pharmaceutical Design Current Clinical Applications of In Vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging
Current Medical Imaging Physiology, Pharmacology and Pathophysiology of the pH Regulatory Transport Proteins NHE1 and NBCn1: Similarities, Differences, and Implications for Cancer Therapy
Current Pharmaceutical Design HIV-1 Tat-Induced Changes in Synaptically-Driven Network Activity Adapt During Prolonged Exposure
Current HIV Research Disorders of Consciousness and Electrophysiological Treatment Strategies: A Review of the Literature and New Perspectives
Current Pharmaceutical Design Bioinformatic Screening of Autoimmune Disease Genes and Protein Structure Prediction with FAMS for Drug Discovery
Protein & Peptide Letters Pramipexole Tachyphylaxis and its Management in Bipolar Depression
Letters in Drug Design & Discovery Subtype-Selective Noncompetitive Modulators of Metabotropic Glutamate Receptor Subtype 1 (mGluR1)
Current Topics in Medicinal Chemistry Advances in Pediatric Epilepsy Surgery
Current Pediatric Reviews GABA and Neuroactive Steroid Interactions in Glia: New Roles for Old Players?
Current Neuropharmacology Recent Developments in Oxidative Processes in Steroid Chemistry
Current Organic Chemistry Therapeutic Role of Zonisamide in Neuropsychiatric Disorders
Mini-Reviews in Medicinal Chemistry Ivabradine: The Hope for a Good Treatment of Ischemic Heart Disease
Current Medicinal Chemistry GABAA/Bz Receptor Subtypes as Targets for Selective Drugs
Current Medicinal Chemistry